Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Oncopeptides, and Sanofi Genzyme.
Community Practice Connections™: Uncovering New Multiple Myeloma Therapies and Their Clinical Applications: Antibodies, CARs, BiTEs, and Beyond
Release Date: August 31, 2021
Expiration Date: August 31, 2022
Acknowledgement of Commercial Support
This activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech
,Inc., administered by Janssen Scientific Affairs, LLC, Oncopeptides, and Sanofi Genzyme.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational program is directed toward medical oncologists and hematologist/oncologists who treat patients with multiple myeloma.
Upon successful completion of this activity, you should be better prepared to:
- Explain the impact of disease-specific factors, risk assessment, and treatment history on therapy selection in RRMM
- Evaluate the safety and efficacy profiles of current and emerging therapies for patients with RRMM
- Implement proactive strategies to identify and minimize the negative impact of treatment-related toxicities in patents with RRMM
- Apply updated guidelines and evidence from landmark trials evaluating emerging therapeutic strategies for RRMM to real-world clinical scenarios of patients with this malignancy
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
Institute Physician, Kraft Family Professor of Medicine, Harvard Medical School
Disclosures: Stock/Shareholder: Scientific Founder and board member, OncoPep, C4 Therapeutics, Inc.; Consultant: Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Precision BioSciences
Associate Professor, Department of Medicine
University of California
San Francisco, CA
Disclosures: Grant Research Support: bluebird bio, inc., Celgene Corporation, a Bristol Myers Squibb Company, Janssen, Nektar Therapeutics, Poseida Therapeutics, Inc., Sutro Biopharma, Inc., TeneoBio; Consultant: Amgen, Bristol Myers Squibb, CareDx, CSL Behring, GSK, Indapta Therapeutics, Karyopharm Therapeutics, Kite Pharma, a Gilead Company, Sanofi
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.